Review



egfr elisa detection kit  (Multi Sciences (Lianke) Biotech Co Ltd)


Bioz Verified Symbol Multi Sciences (Lianke) Biotech Co Ltd is a verified supplier
Bioz Manufacturer Symbol Multi Sciences (Lianke) Biotech Co Ltd manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    Multi Sciences (Lianke) Biotech Co Ltd egfr elisa detection kit
    Vpr peptides released tumor antigens and induced ICD. ( A ) <t>EGFR</t> release was evaluated using an <t>ELISA</t> (n = 5). ( B – D ) The surface exposure of CRT on MC38 ( B ), B16F10 ( C ), and LLC ( D ) cells was evaluated using CLSM. Blue: DAPI; red: CRT. Scale bar, 50 μm. ( E ) The surface exposure of CRT was analyzed using flow cytometry (n = 3). ( F ) ATP release was evaluated using an ATP assay kit (n = 3). ( G ) HMGB1 release was evaluated using an ELISA (n = 3). ( H , I ) Phagocytosis test of Vpr peptides promoting macrophage Ana-1 to phagocytose LLC cells (CFDA-SE labeled), Ana-1 were observed ( H ) and counted ( I ). Green: LLC cells. Scale bar, 50 μm. The data are presented as means ± SD, ** p < 0.0021, *** p < 0.0002, **** p < 0.0001.
    Egfr Elisa Detection Kit, supplied by Multi Sciences (Lianke) Biotech Co Ltd, used in various techniques. Bioz Stars score: 94/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/egfr elisa detection kit/product/Multi Sciences (Lianke) Biotech Co Ltd
    Average 94 stars, based on 2 article reviews
    egfr elisa detection kit - by Bioz Stars, 2026-02
    94/100 stars

    Images

    1) Product Images from "In Situ Vaccination with a Vpr-Derived Peptide Elicits Systemic Antitumor Immunity by Improving Tumor Immunogenicity"

    Article Title: In Situ Vaccination with a Vpr-Derived Peptide Elicits Systemic Antitumor Immunity by Improving Tumor Immunogenicity

    Journal: Vaccines

    doi: 10.3390/vaccines13070710

    Vpr peptides released tumor antigens and induced ICD. ( A ) EGFR release was evaluated using an ELISA (n = 5). ( B – D ) The surface exposure of CRT on MC38 ( B ), B16F10 ( C ), and LLC ( D ) cells was evaluated using CLSM. Blue: DAPI; red: CRT. Scale bar, 50 μm. ( E ) The surface exposure of CRT was analyzed using flow cytometry (n = 3). ( F ) ATP release was evaluated using an ATP assay kit (n = 3). ( G ) HMGB1 release was evaluated using an ELISA (n = 3). ( H , I ) Phagocytosis test of Vpr peptides promoting macrophage Ana-1 to phagocytose LLC cells (CFDA-SE labeled), Ana-1 were observed ( H ) and counted ( I ). Green: LLC cells. Scale bar, 50 μm. The data are presented as means ± SD, ** p < 0.0021, *** p < 0.0002, **** p < 0.0001.
    Figure Legend Snippet: Vpr peptides released tumor antigens and induced ICD. ( A ) EGFR release was evaluated using an ELISA (n = 5). ( B – D ) The surface exposure of CRT on MC38 ( B ), B16F10 ( C ), and LLC ( D ) cells was evaluated using CLSM. Blue: DAPI; red: CRT. Scale bar, 50 μm. ( E ) The surface exposure of CRT was analyzed using flow cytometry (n = 3). ( F ) ATP release was evaluated using an ATP assay kit (n = 3). ( G ) HMGB1 release was evaluated using an ELISA (n = 3). ( H , I ) Phagocytosis test of Vpr peptides promoting macrophage Ana-1 to phagocytose LLC cells (CFDA-SE labeled), Ana-1 were observed ( H ) and counted ( I ). Green: LLC cells. Scale bar, 50 μm. The data are presented as means ± SD, ** p < 0.0021, *** p < 0.0002, **** p < 0.0001.

    Techniques Used: Enzyme-linked Immunosorbent Assay, Flow Cytometry, ATP Assay, Labeling



    Similar Products

    egfr elisa detection kit  (Multi Sciences (Lianke) Biotech Co Ltd)
    94
    Multi Sciences (Lianke) Biotech Co Ltd egfr elisa detection kit
    Vpr peptides released tumor antigens and induced ICD. ( A ) <t>EGFR</t> release was evaluated using an <t>ELISA</t> (n = 5). ( B – D ) The surface exposure of CRT on MC38 ( B ), B16F10 ( C ), and LLC ( D ) cells was evaluated using CLSM. Blue: DAPI; red: CRT. Scale bar, 50 μm. ( E ) The surface exposure of CRT was analyzed using flow cytometry (n = 3). ( F ) ATP release was evaluated using an ATP assay kit (n = 3). ( G ) HMGB1 release was evaluated using an ELISA (n = 3). ( H , I ) Phagocytosis test of Vpr peptides promoting macrophage Ana-1 to phagocytose LLC cells (CFDA-SE labeled), Ana-1 were observed ( H ) and counted ( I ). Green: LLC cells. Scale bar, 50 μm. The data are presented as means ± SD, ** p < 0.0021, *** p < 0.0002, **** p < 0.0001.
    Egfr Elisa Detection Kit, supplied by Multi Sciences (Lianke) Biotech Co Ltd, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/egfr elisa detection kit/product/Multi Sciences (Lianke) Biotech Co Ltd
    Average 94 stars, based on 1 article reviews
    egfr elisa detection kit - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    Vpr peptides released tumor antigens and induced ICD. ( A ) EGFR release was evaluated using an ELISA (n = 5). ( B – D ) The surface exposure of CRT on MC38 ( B ), B16F10 ( C ), and LLC ( D ) cells was evaluated using CLSM. Blue: DAPI; red: CRT. Scale bar, 50 μm. ( E ) The surface exposure of CRT was analyzed using flow cytometry (n = 3). ( F ) ATP release was evaluated using an ATP assay kit (n = 3). ( G ) HMGB1 release was evaluated using an ELISA (n = 3). ( H , I ) Phagocytosis test of Vpr peptides promoting macrophage Ana-1 to phagocytose LLC cells (CFDA-SE labeled), Ana-1 were observed ( H ) and counted ( I ). Green: LLC cells. Scale bar, 50 μm. The data are presented as means ± SD, ** p < 0.0021, *** p < 0.0002, **** p < 0.0001.

    Journal: Vaccines

    Article Title: In Situ Vaccination with a Vpr-Derived Peptide Elicits Systemic Antitumor Immunity by Improving Tumor Immunogenicity

    doi: 10.3390/vaccines13070710

    Figure Lengend Snippet: Vpr peptides released tumor antigens and induced ICD. ( A ) EGFR release was evaluated using an ELISA (n = 5). ( B – D ) The surface exposure of CRT on MC38 ( B ), B16F10 ( C ), and LLC ( D ) cells was evaluated using CLSM. Blue: DAPI; red: CRT. Scale bar, 50 μm. ( E ) The surface exposure of CRT was analyzed using flow cytometry (n = 3). ( F ) ATP release was evaluated using an ATP assay kit (n = 3). ( G ) HMGB1 release was evaluated using an ELISA (n = 3). ( H , I ) Phagocytosis test of Vpr peptides promoting macrophage Ana-1 to phagocytose LLC cells (CFDA-SE labeled), Ana-1 were observed ( H ) and counted ( I ). Green: LLC cells. Scale bar, 50 μm. The data are presented as means ± SD, ** p < 0.0021, *** p < 0.0002, **** p < 0.0001.

    Article Snippet: Cancer cells (HT-29) were treated with Vpr peptides at concentrations of 10, 20, and 40 μM for 48 h. EGFR levels in the cell culture supernatants were subsequently quantified using an EGFR ELISA detection kit (MultiSciences, EK1192-96, Hangzhou, China) according to the manufacturer’s instructions.

    Techniques: Enzyme-linked Immunosorbent Assay, Flow Cytometry, ATP Assay, Labeling